Opioid peptide deltorphin II simulates the cardioprotective effect of ischemic preconditioning: Role of δ2-Opioid receptors, protein Kinase C, and KATP channels

Bulletin of Experimental Biology and Medicine

Volumn 149, Issue 5, 2010, Pages 591-593

  Maslov, L N ^a   Barzakh, E I ^b   Krylatov, A V ^c   Chernysheva, G A ^d   Krieg, T ^e   Solenkova, N V ^f   Lishmanov, A Yu ^g   Cybulnikov, S Yu ^a   Zhang, Y ^a  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

^b TOMSK STATE PEDAGOGICAL UNIVERSITY   (Russian Federation)

^c Jewish Natl and University Library   (Israel)

^d INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f VANDERBILT UNIVERSITY   (United States)

^g ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Heart; Ischemia reperfusion; K ATP channels; Opioid receptors; Protein kinase C

Indexed keywords

17 METHYLNALOXONE; 5 HYDROXYDECANOIC ACID; 7 BENZYLIDENENALTREXONE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CHELERYTHRINE; DELTA 2 OPIATE RECEPTOR; DELTA OPIATE RECEPTOR; DELTORPHIN; GLIBENCLAMIDE; NALTREXONE; NALTRIBEN; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CHANNEL GATING; CONTROLLED STUDY; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; NONHUMAN; QRS COMPLEX; QT INTERVAL; RAT; RECEPTOR UPREGULATION; RR INTERVAL; TREATMENT OUTCOME;

ANIMALS; BENZOPHENANTHRIDINES; BENZYLIDENE COMPOUNDS; DECANOIC ACIDS; GLYBURIDE; HYDROXY ACIDS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL REPERFUSION INJURY; NALTREXONE; OLIGOPEPTIDES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTORS, OPIOID, DELTA;

RATTUS;

EID: 79951620827     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-010-1000-6     Document Type: Article

References (12)

1. R. M. Fryer, A. K. Hsu, H. Nagase, and G. J. Gross, J. Pharmacol. Exp. Ther., 294, No. 2, 451-457 (2000).
2. R. M. Fryer, J. E. Schultz, A. K. Hsu, and G. J. Gross, Am. J. Physiol., 276, No. 4, Pt. 2, H1229-H1235 (1999).
3. J. Kamei, A. Saitoh, M. Ohsawa, et al., Eur. J. Pharmacol., 276, Nos. 1-2, 131-135 (1995).
4. L. N. Maslov and Y. B. Lishmanov, Int. J. Cardiol., 40, No. 2, 89-94 (1993).
5. L. N. Maslov, Y. B. Lishmanov, N. V. Solenkova, et al., Life Sci., 73, No. 7, 947-952 (2003).
6. A. Mattia, T. Vanderah, H. I. Mosberg, and F. Porreca, J. Pharmacol. Exp. Ther., 258, No. 2, 583-587 (1991).
7. J. E. Schultz, A. K. Hsu, and G. J. Gross, Circ. Res., 78, No. 6, 1100-1104 (1996).
8. J. J. Schultz, A. K. Hsu, and G. J. Gross, J. Mol. Cell. Cardiol., 29, No. 8, 2187-2195 (1997).
9. J. el-J. Schultz, A. K. Hsu, H. Nagase, and G. J. Gross, Am. J. Physiol., 274, No. 3, Pt. 2, H909-H914 (1998).
10. D. C. Sigg, J. A. Jr. Coles, P. R. Oeltgen, and P. A. Iaizzo, Am. J. Physiol. Heart Circ. Physiol., 282, No. 6, H1953-H1960 (2002).
11. M. Sofuoglu, P. S. Portoghese, and A. E. Takemori, Life Sci., 52, No. 8, 769-775 (1993).
12. A. Van de Water, J. Verheyen, R. Xhonneux, and R. S. Reneman, J. Pharmacol. Methods, 22, No. 3, 207-217 (1989).